Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Salarius Pharmaceuticals stock

Learn how to easily invest in Salarius Pharmaceuticals stock.

Salarius Pharmaceuticals Inc is a biotechnology business based in the US. Salarius Pharmaceuticals shares (SLRX) are listed on the NASDAQ and all prices are listed in US Dollars. Salarius Pharmaceuticals employs 7 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Salarius Pharmaceuticals

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – SLRX – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Salarius Pharmaceuticals stock price (NASDAQ: SLRX)

Use our graph to track the performance of SLRX stocks over time.

Salarius Pharmaceuticals shares at a glance

Information last updated 2022-01-24.
Latest market close$0.47
52-week range$0.39 - $3.50
50-day moving average $0.58
200-day moving average $0.93
Wall St. target price$4.63
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-0.31

Buy Salarius Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
M1 Finance
Stocks
$0
0%
Free 1-year trial of M1 Plus
when you sign up for M1 Finance
Invest in your favorite stocks or in curated portfolios with automatic rebalancing.
SoFi Invest
Stocks, ETFs, Cryptocurrency
N/A
0%
Get one free stock worth up to $1,000
Open an account
A free way to invest in most equities.
TradeStation
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
$10 of crypto
Open an account with access to crypto
A platform built for all kinds of traders and all styles of trading
Robinhood
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Stash Invest
Stocks, ETFs
$0
$1 per month
$5
Add at least $5 to your Invest account
Stash is more than an investment app. You’ll have access to tools that can help you become a confident investor.
Public
Stocks, ETFs, Cryptocurrency
N/A
$0 per month
Download and sign up with Public.com; approved accounts receive a free stock slice worth up to $300, selected from 9 popular stocks.
Open an account
Commission-free trading in stocks and ETFs with a social networking twist.
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Salarius Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Salarius Pharmaceuticals price performance over time

Historical closes compared with the close of $0.47 from 2022-01-25

1 week (2022-01-19) -6.00%
1 month (2021-12-23) -9.14%
3 months (2021-10-26) -43.82%
6 months (2021-07-26) -44.05%
1 year (2021-01-26) -60.83%
2 years (2020-01-24) -82.78%
3 years (2019-01-25) 43.73%
5 years (2017-01-26) 4.49

Salarius Pharmaceuticals financials

Revenue TTM $3.3 million
Gross profit TTM $-1,680,552
Return on assets TTM -19.36%
Return on equity TTM -32.98%
Profit margin 0%
Book value $0.94
Market capitalisation $21.2 million

TTM: trailing 12 months

Salarius Pharmaceuticals share dividends

We're not expecting Salarius Pharmaceuticals to pay a dividend over the next 12 months.

Have Salarius Pharmaceuticals's shares ever split?

Salarius Pharmaceuticals's shares were split on a 1:25 basis on 21 July 2019. So if you had owned 25 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Salarius Pharmaceuticals shares – just the quantity. However, indirectly, the new 2400% higher share price could have impacted the market appetite for Salarius Pharmaceuticals shares which in turn could have impacted Salarius Pharmaceuticals's share price.

Salarius Pharmaceuticals share price volatility

Over the last 12 months, Salarius Pharmaceuticals's shares have ranged in value from as little as $0.388 up to $3.5. A popular way to gauge a stock's volatility is its "beta".

SLRX.US volatility(beta: 1.63)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Salarius Pharmaceuticals's is 1.6299. This would suggest that Salarius Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Salarius Pharmaceuticals overview

Salarius Pharmaceuticals, Inc. , a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. The company's lead candidate is Seclidemstat (SP-2577), which is in Phase I/II clinical trial for the treatment of advanced solid tumors, including prostate, breast, and ovarian cancers, as well as Ewing sarcoma. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities, as well as a research partnership with the Cancer Epigenetics Institute at Fox Chase Cancer Center to identify new indications and potential biomarkers for Seclidemstat (SP-2577). Salarius Pharmaceuticals, Inc. is headquartered in Houston, Texas. .

Frequently asked questions

What percentage of Salarius Pharmaceuticals is owned by insiders or institutions?
Currently 0.399% of Salarius Pharmaceuticals shares are held by insiders and 19.265% by institutions.
How many people work for Salarius Pharmaceuticals?
Latest data suggests 7 work at Salarius Pharmaceuticals.
When does the fiscal year end for Salarius Pharmaceuticals?
Salarius Pharmaceuticals's fiscal year ends in December.
Where is Salarius Pharmaceuticals based?
Salarius Pharmaceuticals's address is: 2450 Holcombe Boulevard, Houston, TX, United States, 77021
What is Salarius Pharmaceuticals's ISIN number?
Salarius Pharmaceuticals's international securities identification number is: US79400X1072
What is Salarius Pharmaceuticals's CUSIP number?
Salarius Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 33938A105

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site